CRISPR Therapeutics - CRSP Stock Forecast, Price & News

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRSP shares.
View CRSP analyst ratings or view top-rated stocks.

16 equities research analysts have issued 12 month target prices for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $46.00 to $220.00. On average, they predict the company's share price to reach $112.33 in the next year. This suggests a possible upside of 78.0% from the stock's current price.
View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts.

CRISPR Therapeutics' stock was trading at $75.78 on January 1st, 2022. Since then, CRSP stock has decreased by 16.7% and is now trading at $63.10.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our CRSP earnings forecast.

CRISPR Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings results on Monday, August, 8th. The company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($2.23) by $0.17. The firm earned $0.20 million during the quarter, compared to analyst estimates of $2.20 million. CRISPR Therapeutics had a negative net margin of 4,274.02% and a negative trailing twelve-month return on equity of 27.40%. The business's quarterly revenue was down 100.0% on a year-over-year basis. During the same period in the previous year, the business posted $9.44 EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

CRISPR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (5.92%), Nikko Asset Management Americas Inc. (5.92%), Price T Rowe Associates Inc. MD (3.86%), FMR LLC (2.08%), State Street Corp (2.01%) and Loomis Sayles & Co. L P (1.80%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends.

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRSP stock can currently be purchased for approximately $63.10.

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $4.92 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or ($8.23) on an earnings per share basis.

The company employs 473 workers across the globe.

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.